Adolor reiterated at outperform by RBC

Adolor Corp. was reiterated by analyst Michael J. Yee at outperform, above average risk, with a $25 price target. The analyst believes the shares will climb over the next 12 months based in part on approval of alvimopan by November and further clinical development of a co-formulated alvimopan/opioid pill. Shares of the Exton, Pa.-based biopharmaceutical company were down 23 cents, or 0.97%, at $23.58 on volume of 370,281 shares versus the three-month running average of 413,583 shares. (Nasdaq: ADLR)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.